LP268095-9
Eculizumab
Active
Description
Eculizumab is monoclonal antibody that binds to the C5 complement component and is used to treat atypical hemolytic uremic syndrome (aHUS). aHUS is characterized by hemolytic anemia that leads to the presence of schistocytes, thrombocytopenia, renal damage, and other organ system impairment. aHUS is caused by a rare genetic mutation that interferes with the regulation of the complement system and leads to thrombotic microangiopathy (TMA). Prior to the development of eculizumab, the only treatment for aHUS was plasmapheresis, which did not stop progressive organ impairment. Eculizumab is an extremely expensive but effective therapy against aHUS and provides good outcomes and improved quality of life for patients with aHUS. Eculizumab has also been found to increase the possibility for the repair of renal damage. PMID: 27766045Measurement of eculizumab in serum is used for monitoring and therapy optimization. Source: Regenstrief LOINC
Basic Part Properties
- Part Display Name
- Eculizumab
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2018-07-18
- Construct for LOINC Short Name
- Eculizumab
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP268095-9
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| es-ES | Spanish (Spain) | Eculizumab |
| it-IT | Italian (Italy) | Eculizumab |
| zh-CN | Chinese (China) | 依库珠单抗 Synonyms: 依库组单抗; |
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright